Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 7:10:95.
doi: 10.4103/ijpvm.IJPVM_116_18. eCollection 2019.

Leishmania Vaccines Entered in Clinical Trials: A Review of Literature

Mohammad Moafi  1 , Hossein Rezvan  1 , Roya Sherkat  2 , Roya Taleban  3
Affiliations
Review

Leishmania Vaccines Entered in Clinical Trials: A Review of Literature

Mohammad Moafi et al. Int J Prev Med. .

Abstract

Leishmaniasis is considered as a zoonotic infection and neglected tropical disease. Leishmania treatment is not totally successful and imposes high expenditures, especially in developing countries. Since the natural infection leads to the robust immunity in most of the human cases, many bodies of research have been focusing on Leishmania vaccines, being capable to control Leishmania infection. First generation vaccines (such as Leishmune® and CaniLeish®) have proved robust protective immunity in dogs. In human, recombinant vaccines, including Leish-F1 could confer some degrees of protective immunity against natural infection. Recently, ChAd63-KH DNA vaccine has been accomplished in providing prevention against Leishmania infection; however, this vaccine should be further evaluated in other clinical trials.

Keywords: Leishmania donovani; Leishmania major; Leishmania mexicana; Leishmania vaccines; Leishmnia amazonensis.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Diagram showing mechanism of action and the most important outcome of the vaccines
See this image and copyright information in PMC

References

    1. Moafi M, Rezvan H, Sherkat R, Taleban R, Asilian A, Esfahani SH, et al. Evaluation of IL-12RB1, IL-12B, CXCR-3 and IL-17a expression in cases affected by a non-healing form of cutaneous leishmaniasis: An observational study design. BMJ Open. 2017;7:e013006. - PMC - PubMed
    1. Ali S, Rezvan H, McArdle S, Khodadadi A, Asteal F, Rees R. CTL responses to Leishmania mexicana gp63-cDNA vaccine in a murine model. Parasite Immunol. 2009;31:373–83. - PubMed
    1. Gannavaram S, Bhattacharya P, Ismail N, Kaul A, Singh R, Nakhasi H. Modulation of innate immune mechanisms to enhance vaccine induced immunity: Role of co-inhibitory molecules. Front Immunol. 2016;7:187. - PMC - PubMed
    1. Rezvan H, Moafi M, editors. Veterinary Research Forum. Urmia, Iran: Faculty of Veterinary Medicine, Urmia University; 2015. An overview on Leishmania vaccines: A narrative review article. - PMC - PubMed
    1. Moafi M, Rezvan H, Sherkat R, Taleban R, Asilian A, Hamid Zarkesh-Esfahani S, et al. Comparison of pro-inflammatory cytokines of non-healing and healing cutaneous leishmaniasis. Scand J Immunol. 2017;85:291–9. - PubMed